Sugi Predict

Sugi Predict / Compounds / SCHEMBL199980

SCHEMBL199980

SCHEMBL199980

O=C(O)[C@@H](Cc1ccccc1)NF

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 2/20 0.57
▸ MMP2 P08253 4/20 0.57
▸ MMP9 P14780 3/20 0.57
▸ ADAMTS4 O75173 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.56
▸ CYP1A2 P05177 1/20 0.55
▸ NAALAD2 Q9Y3Q0 2/20 0.54
▸ FOLH1 Q04609 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ ACE P12821 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ ALPI P09923 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ PTGS1 P23219 1/20 0.52
▸ XIAP P98170 1/20 0.52
▸ SLC7A5 Q01650 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144009 1.00 MME (0.57) MMEMMP2MMP9ADAMTS4NPSR1
SCHEMBL31345792 1.00 MME (0.57) MMEMMP2MMP9ADAMTS4NPSR1
SCHEMBL144008 1.00 MME (0.57) MMEMMP2MMP9ADAMTS4NPSR1
Trifluoroacetic Acid SCHEMBL31261334 0.93 ACE (0.55) MMEMMP2MMP9ADAMTS4NPSR1
SCHEMBL8501294 0.86 NAALAD2 (0.47) MMEMMP2MMP9ADAMTS4NPSR1
SCHEMBL1008925 0.85 FOLH1 (0.56) MMENAALAD2FOLH1L3MBTL1ACE
SCHEMBL22290826 0.85 ALDH1A1 (0.57) MMEFOLH1ACEALDH1A1
SCHEMBL29964738 0.85 ALDH1A1 (0.57) MMEFOLH1ACEALDH1A1
SCHEMBL1008926 0.85 FOLH1 (0.56) MMENAALAD2FOLH1L3MBTL1ACE
SCHEMBL15833929 0.85 EPHX1 (0.53) MMENPSR1CYP1A2ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120001347-A Preparation method and application of Raman signal enhanced molecularly imprinted magnetic inverse opal photonic crystal microsphere 南京师范大学 2025-05-16 — — CN claimed
US-20250186427-A1 METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS UNIVERSITY OF WASHINGTON 2025-06-12 — — US disclosed
CN-120001347-A Preparation method and application of Raman signal enhanced molecularly imprinted magnetic inverse opal photonic crystal microsphere 南京师范大学 2025-05-16 — — CN disclosed
US-20240252484-A1 Methods and Compositions for Treating Vasomotor Symptoms UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2024-08-01 — — US disclosed
US-20220125781-A1 Methods and Compositions for Treating Vasomotor Symptoms UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2022-04-28 — — US disclosed
EP-3982980-A1 NEOANTIGEN COMPOSITIONS AND USES THEREOF BioNTech US Inc. (US) 2022-04-20 — — EP disclosed
WO-2020252039-A1 NEOANTIGEN COMPOSITIONS AND USES THEREOF BIONTECH US INC. (US) 2020-12-17 — — WO disclosed
US-10633630-B2 Acceleration of Mycobacterium growth ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2020-04-28 — — US disclosed
EP-3158053-B1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) 2019-03-13 — — EP disclosed
US-9913884-B2 HLA-A2 tumor associated antigen peptides and compositions OSE PHARMA INTERNATIONAL SA (CH) 2018-03-13 — — US disclosed
WO-2006106311-A2 COMBINATION TREATMENT METHODS FOR TREATING SEX-HORMONE DEPENDENT DISEASE AND FERTILITY TREATMENT MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2006-10-12 — — WO disclosed
EP-1613357-A1 GONADOTROPIN RELEASING HORMONE ANALOGUE CONJUGATES WITH STEROID HORMONES Ardana Bioscience Limited (GB) 2006-01-11 — — EP disclosed
WO-2005100385-A2 COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY ALLIGATOR BIOSCIENCE AB (PUBL) (SE) 2005-10-27 — — WO disclosed
EP-1576108-A2 NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM DIVERSA CORPORATION (US) 2005-09-21 — — EP disclosed
WO-2004087215-A1 GONADOTROPIN RELEASING HORMONE ANALOGUES CONJUGATES WITH STEROID HORMONES ARDANA BIOSCIENCE LIMITED (GB) 2004-10-14 — — WO disclosed
US-20040014195-A1 Nitrilases, nucleic acids encoding them and methods for making and using them DIVERSA CORPORATION (US) 2004-01-22 — — US disclosed
US-20040002147-A1 Nitrilases DIVERSA CORPORATION 2004-01-01 — — US disclosed
WO-2003097810-A2 NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM DIVERSA CORPORATION (US) 2003-11-27 — — WO disclosed
US-20030124698-A1 Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia DIVERSA CORPORATION 2003-07-03 — — US disclosed
WO-2002022844-A1 OPTICALLY ACTIVE FLUOROPHENYLALANINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME KANEKA CORPORATION (JP) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252484-A1 Methods and Compositions for Treating Vasomotor Symptoms VASP, PDE3A, PDE2A MME 1103/4885MMP2 2133/4885MMP9 2272/4885
US-20040014195-A1 Nitrilases, nucleic acids encoding them and methods for making and using them RNGTT, NSUN2, NSUN3 MME 304/4885MMP2 1379/4885MMP9 1769/4885
US-20040002147-A1 Nitrilases RNGTT, DNTT, NOP2 MME 162/4885MMP2 1344/4885MMP9 1904/4885
US-20030124698-A1 Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia NIT2, DNPH1, ASNS MME 201/4885MMP2 1051/4885MMP9 1377/4885
US-20250186427-A1 METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS VASP, PDE3A, PDE2A MME 1103/4885MMP2 2133/4885MMP9 2272/4885
US-20220125781-A1 Methods and Compositions for Treating Vasomotor Symptoms VASP, PDE3A, PDE2A MME 1103/4885MMP2 2133/4885MMP9 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.